Results 181 to 190 of about 221,867 (307)
Objective Rituximab, a CD20+ B cell depletion therapy, is frequently used to treat systemic lupus erythematosus (SLE). However, variability in patient response highlights the need for a deeper understanding of the underlying immune cell dynamics of B cell depletion and repopulation.
Haerin Jang +9 more
wiley +1 more source
Non-Conventional and Emerging Autoantibodies in Sjögren’s Disease
Adrian YS Lee1,2 1Department of Clinical Immunology & Allergy, Westmead Hospital & ICPMR, Sydney, NSW, Australia; 2Centre for Immunology & Allergy Research, Westmead Institute for Medical Research, The University of Sydney, Sydney, NSW ...
Lee AYS
doaj
Factors associated with interstitial lung disease among patients with idiopathic inflammatory myopathies. [PDF]
Wilkerson JC +8 more
europepmc +1 more source
Objective Systemic lupus erythematosus (SLE) shows clinical and molecular heterogeneity, and cardiovascular (CV) complications and lupus nephritis (LN) remain leading causes of morbidity and mortality. This study investigated whether omic profiling can reveal molecular endotypes linked to these outcomes.
Tomás Cerdó +84 more
wiley +1 more source
Local IgG autoantibody profiles in hidradenitis suppurativa and their associations with disease features and anti-TNF therapy. [PDF]
Carmona-Rivera C +4 more
europepmc +1 more source
Objectives Still's Disease represents a prototypical polygenic systemic autoinflammatory diseases (SAIDs), characterized by recurrent systemic inflammation and dysregulation of innate immunity. Despite extensive clinical characterization, familial clustering Still's disease remains unreported.
Longfang Chen +23 more
wiley +1 more source
Clinical utility of human leukocyte antigen genotyping and immunoglobulin G4 autoantibody testing in autoimmune neurological diseases: A focused minireview. [PDF]
Bouayad A.
europepmc +1 more source
Objective Regeneration and expansion of Treg by low‐dose interleukin‐2 (IL‐2) therapy is considered a potential treatment strategy for a wide range of autoimmune diseases. To provide a pathophysiologically‐based rationale for low‐dose IL‐2 therapy, we investigated whether reversible defects in the Treg–IL‐2 axis emerge in inflammatory myopathies ...
Justus Ohmes +10 more
wiley +1 more source
Association of G-Protein-Coupled Receptors autoantibodies with vasoregulation in Post-COVID. [PDF]
Seibert FS +9 more
europepmc +1 more source

